Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | v416687_ex31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | v416687_ex31-2.htm |
| 10-Q - 10-Q - ENZON PHARMACEUTICALS, INC. | v416687_10q.htm |
| EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC. | v416687_ex32-1.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarterly period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard L. Feinstein, Vice President-Finance and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| August 7, 2015 | /s/ Richard L. Feinstein |
| Richard L. Feinstein | |
| Vice President-Finance and Principal Financial Officer | |
| (Principal Financial Officer) |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.